Remarkably, circulating IGFBP-6 resulted significantly reduced after the treatment with the GHRH-analogue Tesamorelin, which reduces liver fat and prevents fibrosis in patients with NAFLD [61]. This evidence concerns the gene IGFBP6 and metabolic dysfunction-associated steatotic liver disease.